Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
News for 'CYGX'
CytoGenix, Inc. Board Appoints Industry Veteran Lex M. Cowsert, PhD as President, Chief Executive Officer and Director
HOUSTON, Nov 18, 2008 (BUSINESS WIRE) -- CytoGenix, Inc. (OTCBB:CYGX) today
announced that its Board of Directors has appointed veteran pharmaceutical
executive Dr.Lex M. Cowsert to the positions of President, Chief Executive
Officer, and Director, effective immediately. Randy Moseley, who was serving as
Interim Chief Executive Officer until a permanent replacement was named,
simultaneously resigned as Interim CEO but will continue in his role as Chairman
of the Board and Principal Financial Officer.
The appointment of Dr. Cowsert as President, CEO and Director significantly
strengthens CytoGenix's management team as the Company enters a new stage in
corporate development. Dr. Cowsert will lead the team at CytoGenix to implement
a stronger business and commercialization plan, and tighter revenue generating
strategies during this new phase of development.
"We are delighted that Dr. Cowsert is joining the team to lead CytoGenix in this
exciting stage of growth and expansion. His industry expertise in
commercialization and business development complements our current management
team and brings a new and more directed business approach to the Company," said
Mr. Moseley.
Director, Cy Stein goes on to say, "I have known Lex Cowsert for many years,
and, on behalf of the Board of Directors look forward to working with him, and
toward implementing his vision for the future of CytoGenix. We are delighted
that a person with Dr. Cowsert's extensive experience in biotech and proven
management skills has taken the position of CEO."
"I am very pleased to be joining the CytoGenix team. CytoGenix is in a pivotal
stage of its corporate development, transitioning from a discovery company to a
product development company. I am looking forward to working with the Company's
current management, its dedicated staff, and our team of world-renowned
collaborators in a concerted effort to further advance and commercialize our
platform technologies and to build shareholder value," said Dr. Cowsert.
About Dr. Cowsert
Dr. Cowsert has over 19 years of experience in drug discovery and development.
He is currently a co-founder and serves as the Chief Scientific Officer of
BellairePharma, Inc., founded in 2007, and is co-founder and CSO of
HoustonPharma, Inc., founded in 2005. From 2002 to 2006 Dr. Cowsert served as
CSO of Automated Cell, Inc., an imaging-based technology company engaged in drug
discovery and development. From 2000 to 2002 he was VP of Functional Genomics
for VistaGen Therapeutics, Inc., a stem cell-based technology company engaged in
drug discovery and development. From 1989-2000 Dr. Cowsert held a series of
positions of increasing responsibility in the scientific and clinical
development programs at Isis Pharmaceuticals, Inc. Dr. Cowsert is sole inventor
on 19 issued US Patents and a named inventor on 119 issued US Patents. Dr.
Cowsert received his BS in biology from the University of Florida and earned his
PhD in Molecular Biology from Georgetown University. Dr. Cowsert completed his
post-doctoral work at the National Cancer Institute where he successfully
competed for and was awarded an NCI Intramural Research Training Award (1987),
National Research Service Award (1988), and an NCI Biotechnology Training
Fellowship (1989).
Dr. Cowsert has a broad range of experience and expertise in both
entrepreneurial and public company settings including: technology development;
drug discovery and development; regulatory reports; FDA interactions; venture
capital and private equity; US and foreign patent applications; negotiating and
managing industrial and academic collaborations; and identifying, negotiating
and in-licensing technologies for commercial development. He has successfully
applied for and managed SBIR and RO1 government grants.
News!
News for 'CYGX' - (CytoGenix Announces Award of SBIR Grant from the National Institutes of Health)
HOUSTON, Jun 26, 2008 (BUSINESS WIRE) -- CytoGenix, Inc. (CYGX), today
announced that the National Institute of Allergy and Infectious Diseases of NIH
has awarded a Phase I Small Business Innovation Research Grant (SBIR) to
CytoGenix, Inc. Dr. Frederic Kendirgi will be the principal investigator. The
grant entitled, "Novel DNA Manufacturing Process: Cell-Free Production and
Testing of a New Multivalent DNA Vaccine Against Human Influenza (H5N1)"
received an award of approximately $136,000.
Dr. Kendirgi comments, "The emergence of highly pathogenic avian influenza
viruses in domestic poultry and the increasing number of cases derived from
direct transmission of avian influenza viruses to humans are a significant
threat to public health. Currently, no robust vaccines against potentially
pandemic avian flu viruses are available to the general public.
Results from this grant may pave the way for a new generation of DNA vaccines
against influenza virus strains using our synDNA(SM) production process which
can be rapidly adapted to new viral strains. This acknowledgement of our
technology allows us to put this process to trial by focusing on a potential
medical emergency.
If successful, we hope to routinize our vaccine production platform and apply
the experience gathered to generate synDNA(SM) vaccine candidates against other
pathogen causing diseases such as malaria, AIDS or tuberculosis to which
effective vaccines prepared by conventional methods have shown disappointing
results."
Dr. Malcolm Skolnick, CytoGenix CEO adds, "Award of this peer reviewed,
competitive grant provides support for CytoGenix's ongoing research and
development efforts as well as external validation of the synDNA(SM) vaccine
technology. The Company will utilize the results from this Phase I grant to
develop our application for further funding in additional phases of the SBIR
program."
SAFE HARBOR: Except for statements of historical fact, the statements in this
press release are forward-looking. Such statements are subject to a number of
risks and uncertainties that could cause actual results to differ materially
from the statements made. These factors include, but are not limited to, general
economic conditions, risks associated with the acceptance of new products,
competition, and other factors more fully detailed in the Company's filings with
the Securities and Exchange Commission. Additional information about CytoGenix
and its technology can be found on the website at www.cytogenix.com.
SOURCE: CytoGenix, Inc.
Skoob, you will never see anything posted about a patent app being rejected. Why? Because the vast majority of patent apps I have seen over the years have endured several rejections. The rejection notices were hard, cruel and seemed final. But they are not final, you have to keep re-submitting with slightly different wording and clarity. Standard procedure for the patent office, they make you work for it.
Wawh - see my last post below, #49638, it was mentioned in the CYGX PR from March regarding the US Army Medical Research Institute of Infectious Diseases (USAMRIID).
JJ - the US Army Medical Research Institute of Infectious Diseases (USAMRIID) is going to be there, including the woman who is heading up the CYGX collaboration, Dr. Connie Schamaljohn.
This was the CYGX PR in March:
CytoGenix and USAMRIID to Collaborate in Developing Biodefense synDNA™ Vaccines
Houston, TX (27 March 2007) CytoGenix, Inc. (CYGX.OB) announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID).
Scientists from CytoGenix and USAMRIID, led by Dr. Connie Schmaljohn, intend to develop and test synDNA™ vaccines for the prevention of disease caused by the Ebola virus and several strains of equine encephalitis viruses.
Dr. Malcolm Skolnick, CytoGenix Chief Executive Officer, stated, "We are pleased to have the opportunity to work with Dr. Schmaljohn and the USAMRIID team at Fort Detrick. These disease targets are listed as Category A & B bioterrorism agents/diseases by the Centers for Disease Control. Data collected under this CRADA will help to demonstrate the validity of use of synDNA™ vaccines in rapid response platforms including the protection of our nation's military personnel, health providers and other first responders, as well as the general population against a spectrum of existing and emerging terroristic and other infectious diseases."
NEWS NEWS NEWS....
News for 'CYGX' - (CytoGenix and Eurogentec Align on synDNA(TM)
Development)
HOUSTON, May 10, 2007 (BUSINESS WIRE) -- CytoGenix, Inc. (OTCBB:CYGX)
announcedtodaythat it has executed a Letter of Intent regarding synDNA(TM) development
with Eurogentec S.A.The Companies have identified an area of mutual interest regarding
developmentofsynDNA(TM) and will collaborate to optimize manufacturing and to implement
purification and quality control parameters. A successful collaboration
willfacilitatesubmission of European Union (EU) regulatory filings with products
containing synDNA(TM).Malcolm Skolnick, CytoGenix President/CEO, stated, "Eurogentec is an
excellentprocessdevelopment partner for synDNA(TM). The collaboration will allow us to
accelerate the entry of synDNA(TM) as a drug substance for clients within
theEU.Eurogentec brings a wealth of process development and EU regulatory filing
experience to the collaboration."Dr. Phillippe Cronet, Director of Eurogentec's Biologics Business Unit,
commented, "CytoGenix synDNA(TM) has the potential to make a significant
impactasa source of drug substance for a wide array of DNA-based medicine. We are
looking forward to establishing a collaborative relationship with
CytoGenix."CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops
andmarketsinnovative products and services based on its proprietary synDNATM
production and ssDNA expression technology. The company has developed abreakthroughsynthetic process for large-scale production of high purity DNA
that can be made faster and cleaner than production using traditionalfermentationmethods and has developed a novel expression vector that enables
production of ssDNA sequences inside the cell. CytoGenix currently holds
11grantedpatents and about 36 international or US pending patent applications
claiming methods and materials in connection with these platform
technologies.Regarding Eurogentec
Eurogentec was founded in 1985 as a spin-off of the University of Liege(Belgium).Its mission is to design and deliver reliable and innovative services
and products for the Life-Science community. As a leading supplier for
genomicandproteomic research, Eurogentec is able to offer its customers integrated
solutions, whether they use DNA, antibodies, peptides or proteins as
researchtools.Eurogentec also offers research and development services for the
biopharmaceutical industry.During the past years, Eurogentec has developed a broad platform of
enablingtechnologies.The activities are organised around 2 business units.
The Tools for Genomics and Proteomics department offers oligonucleotidesynthesiswith a large range of modifications, oligonucleotides for In Vitro
Diagnostic (IVD), Real-Time PCR products, DNA MicroArray services and a
widerangeof kits and consumables. It also gathers know-how in the design of
peptides, either for antibody production or bioactive peptide purposes.
Antibodyproductionin a wide range of animal models as well as Peptide-, Antibody- and
ProteinArrays are also amongst its expertise.Eurogentec's Biologics unit is a full-service Contract Manufacturing
Organisation (CMO) delivering research, development and production
services forcGMPclinical batch manufacturing.
The EGT Group currently employs around 300 people, including around 30
PhDs. In2001,Eurogentec has been awarded "Belgium's entrepreneur of the Year." In 2002,
Eurogentec received the Walloon Region award for exports in Europe.SAFE HARBOR: Except for statements of historical fact, the statements in
thispressrelease are forward-looking. Such statements are subject to a number of
risks and uncertainties that could cause actual results to differ
materiallyfromthe statements made. These factors include, but are not limited to,
generaleconomicconditions, risks associated with the acceptance of new products,
competition, and other factors more fully detailed in the company's
filings withtheSecurities and Exchange Commission. Additional information about CytoGenix
and its technology can be found on the website at www.cytogenix.com.SOURCE: CytoGenix, Inc.
CONTACT: CytoGenix, Inc., HoustonCEOMalcolm Skolnick,
713-789-0070http://www.cytogenix.com/orEurogentec S.A.CEOJean-Pierre
Delwart, + 32 4 372 74 00j.p.delwart@eurogentec.comorDirector
BiologicsPhilippe Cronet, + 32 4 372 74
00ph.cronet@eurogentec.comorCommunication ManagerIsabelle Body, + 32 4 372
74 00i.body@eurogentec.comFax: + 32 4 372 75
00info@eurogentec.comwww.eurogentec.comCopyright Business Wire 2007
nw_la, my advice is to buy as much CYGX as you can afford to lose and average down your cost.
The December up trend didn't continue in 2006, so I wouldn't count on the Summer trend continuing either, especially after losing so much in the past year.
CYGX website used to list Kurt Berens and Dr. Ma
as key employees, but they are no longer listed, are they still with the company?
I emailed CYGX tonight asking for the Shareholders Meeting date/time. I'm thinking of attending this year. Anyone else?
LongJohn
OT: fearfrost - "strong positive side-effects", can you elaborate?
Thanks Sanoman, even a blind squirl finds a nut now and again. :)
PR next week is my next prediction, a.k.a. wild guess.
Peace out
Here we are again... "When everyone is selling, buy buy buy and when they're buying, sell sell sell"... Rodney Dangerfield
We've seen it happen time and time again over the years. We are on the verge of a 50 cent up swing after getting some news, IMHO. I have nothing to gauge this on except past performance of this stock... it tends to bottom out on high volumn, then volumn halts down to nothing for a few days or weeks, then the price swings up on a series of news. Check the history of this stock and you'll see.
Holycow - nice post
I could not have said it better.
I'm buying more shares on Wednesday.
Happy New Year to the long and strong!
themuzicmen - did you hear about the big news at CYGX this week regarding LW and FV getting fired? Also recently, the deal to build an office building/synDNA plant? Looks like they are gearing up to go to the next level (including IND's finally submitted in 2007).
Now is a good time to buy CYGX, @.70... but from reading your new board, it sounds like you're in for 1 to 3 days and out. CYGX is more like 30 days+ in and out and therefore more risky.
Just thought I would drop you a line, wondered where you went.
Good luck to you! Drop a note on the CYGX board sometime.
BigB poll - SP will close @ .73
SP at COB Monday: .93
Great start to the PR season! Patience is paying off, this stuff takes time. Longs who held will be rewarded handsomely in 2007. And real estate prices are down, a wonderful thing.
NEWS NEWS NEWS...
HOUSTON, Nov 03, 2006 (BUSINESS WIRE) -- CytoGenix, Inc. (OTCBB:CYGX)
announces
the conclusion of negotiations with GSL Constructors, Ltd for the
design/build
development of a $3.8 million, 20,000 sq. ft. facility in Houston's
Westchase
District. The building will be located on a two and one-third acre site in
the
Oak Park at Westchase office park and constructed by GSL's affiliate,
Kingham
Dalton Wilson whose experience spans over 110 years and 1,000 projects.
CytoGenix plans to occupy the building in the fourth quarter of 2007.
The new facility will be the company's headquarters and provide the space
for
growth and expansion of DNA manufacturing capacity. The building will
contain
approximately 8,000 sq. ft. of state-of-the-art, GMP-qualified clean-room
space
for production of clinical-grade synDNA(TM), the company's proprietary
synthesized DNA. This area will house several production suites with
capacity to
produce 50 grams of high purity DNA daily.
Dr. Malcolm H. Skolnick, CytoGenix President and CEO, commented, "This is
a very
important step in the evolution of our company and bringing increasing
value to
our shareholders. This investment will allow us to manufacture GMP grade
material for our synDNA(TM) influenza vaccines and for our herpes
antiviral
product Simplivir(TM), as well as, supplying a growing market for clinical
grade
DNA. Once fully staffed, this facility will employ approximately 200
scientists,
technicians and other professionals. We are very happy to make this
contribution
to Houston's economic development."
Mr. Welcome Wilson, Jr., President of GSL, stated, "One of the best things
about
my job is that I get to know and work with many different kinds of
businesses.
I'm excited about the promise and the potential of the biotech industry in
Houston and about CytoGenix in particular." Brad Berry of GSL added, "We
view
our clients as partners and as such will deliver a premium product on
time."
More News!
HOUSTON, Jun 29, 2006 (BUSINESS WIRE) -- CytoGenix, Inc. (OTCBB:CYGX) Dr.
Yin
Chen, CytoGenix Chief Scientific Officer; Ms. Harilyn McMicken, CytoGenix,
Laboratory Director; Dr. Cy Stein, Professor of Medicine at Albert
Einstein
School of Medicine; and Dr. John Rossi, Chairman and Professor in the
Division
of Molecular Biology, City of Hope have collaborated in a study that has
been
accepted for publication in the peer-reviewed journal Clinical Cancer
Research.
Drs. Stein and Rossi are directors of the company and members of its
scientific
advisory board.
The paper titled "The Function of Bcl-2 Protein in 518A2 Melanoma Cells In
Vivo
Differs Dramatically from its In Vitro Role" presents data from
experiments
performed on mice xenografted with human melanoma tumors and demonstrates
that
Bcl-2 protein could be an important therapeutic target in reducing or
regressing
tumors.
Dr. Cy Stein, the lead investigator, states, "This study helps to validate
the
use of the CytoGenix proprietary ssDNA technology in settings where
permanent
down-regulation of gene expression is needed, leading in this case, to
unexpected and dramatic results."
Dr. Yin Chen states, "This is a significant step forward for CytoGenix
because
it is the first time that the company's ssDNA technology has been shown to
be
effective an in vivo cancer model."
CYGX has developed an ice cream cone that tastes great (high quality/effectiveness), has only 5 calories per serving (exceeds our expectations) and only costs 5 cents (low price).
Oh, and CYGX can supply it quickly to the anticipated customer demand if that should materialize. Unbelievable potential here if the "free samples" continue to prove successful in 2006, IMO.
I smell revenue too... even more importantly I smell a low cost, high quality, highly effective synDNA product!
Starting to smell long term potential here. I also sense the need for CYGX to be confidential on the buyer, could be a big player that has requested it this way in order to avoid current supplier issues. We're sitting on something really big here if it takes off.
News News News...
HOUSTON, Jun 13, 2006 (BUSINESS WIRE) -- CytoGenix, Inc. (OTCBB:CYGX)
announced
a follow-on order for the production of synDNA(TM) from a client referred
by
Aldevron, LLC (Fargo, ND).
The current order for synDNA(TM) was placed after the initial batch of
synDNA(TM) proved to be the preferred material for use in the manufacture
of
innovative products by the client. While the details of the order were not
disclosed, success in the next, final series of tests could result in
future
orders for gram quantities of custom synDNA(TM) material to satisfy the
client's
anticipated demand.
"The CytoGenix synDNA(TM) technology is ideally suited for many of our
clients
when conventional plasmid DNA is too costly or difficult to produce,"
stated
Michael Chambers, President and CEO of Aldevron. "The first order of
synDNA(TM)
met and exceeded our expectations in terms of quality, cost, and
turn-around
time."
"The relationship between CytoGenix and Aldevron continues to be mutually
beneficial," said Malcolm Skolnick, President and CEO of CytoGenix. "We
are
delighted to service clients by utilizing our excess production capacity
thereby
generating revenue to fund our internal product development programs."
Bigworld great advice to the guy who bailed out, you told him...
"Rather than sell, as you have, you should have added more shares on weakness" and "Next time, sell after your stock has had a nice run up. Sell into strength. Buy on weakness".
I've added 10k shares recently under a buck, what a great opportunity to buy IMO. I'm glad to take the shares away from the guy who bailed. Good luck to all.
BigB - one of the greatest movies of all times. <eom>
This is the best time to BUY BUY BUY...
Downregul8 and Neo43 thanks!
More on my question in my last post
And please excuse my lack of understanding of bio-tech.
["Is it possible for successful validation of the CYGX synDNA process without having the DNA vaccine process validation or do they go hand in hand?"]
More specifically, if the DNA vaccine validation takes 4 years to validate, are we also waiting 4 years for synDNA validation within the Hep B application? Also, if synDNA does not work for one particular vaccine, does that mean it won't work for any DNA vaccine process or is it possible that it will work for some cures but not others?
Paulness, I enjoyed the article on Aldevron
and their DNA vaccine process:
["The company has formed partnerships with several small and large genetic research companies.
Aldevron participated in a just-completed animal study that successfully tested a DNA vaccine for Hepatitus B."]
From CYGX website:
["CytoGenix, Inc. (CYGX: OTC: BB) and Aldevron, LLC announced positive results of a pilot study using Cytogenix synDNA™ as the active ingredient in a Hepatitis B vaccine, demonstrating that it is highly effective in generating an immune response".]
If we only knew the status of this now, let's hope we hear something soon. The 3 to 4 year timeframe mentioned for DNA vaccine validation is not exactly great news. Is it possible for successful validation of the CYGX synDNA process without having the DNA vaccine process validation or do they go hand in hand?
Everyone stop whining and buy more shares of CYGX
This is a golden opportunity for us to increase our positions in CYGX and it may be the last time it will be below 1.30
If you cannot afford more shares right now, then sit back and relax, it will go back up on positive news, which I'm guessing will be coming soon.
Soon is 3 to 6 months...
I'd be very surprised if we did not hit 2.00 by summer.
We need news to go to 2.00, really? LOL
Yes of course we need news and with all the possible avenues for news right now (synDNA sales, bio-terrorism contracts, animal trial successes, etc.), I would expect something soon.
BTW - I actually fat fingered the "2.00 by 5/1", prediction. I meant 5/15, I missed the 5. This is my story and I'm sticking to it.
On our way to $2.00, here's how and possibly when...
Historical PPS for CYGX:
01/03/06 - 1.15
02/01/06 - down 25% to .86
03/31/06 - up 75% to 1.51
Following this pattern (approximately) going forward, here's our future PPS:
4/28/06 - down 25% to 1.14
6/28/06 - up 75% to 2.00
My guess is the percentages up and down may be somewhat reasonable but the time it will take to go back up should be significantly less if we get some news sooner. My guess is we'll be at 2.00 by 5/1/06.
CytoGenix Enters into a Supply Agreement with GE Healthcare for DNA Production Reagents
HOUSTON, Mar 23, 2006 (BUSINESS WIRE) -- GE Healthcare, a unit of General Electric Company (GE), and CytoGenix, Inc. (CYGX) have entered into a supply agreement in which GE Healthcare will provide CytoGenix with DNA production reagents for use in the manufacture of vaccines and therapeutic compounds by CytoGenix.
Under the terms of the agreement, GE Healthcare has agreed that CytoGenix will be its exclusive customer for these reagents where the intended application is the manufacture of therapeutic compounds using CytoGenix' proprietary processes.
CytoGenix' proprietary synDNA(TM) is a cell-free production process that enables a more efficient manufacturing cycle than extraction of DNA from bacterial fermentation. CytoGenix expects to begin production of commercial-scale amounts of synDNA(TM) in April and continue development of DNA vaccines and therapeutic products against infectious diseases (herpes infections, multi-drug resistant bacterial infections), inflammatory disorders (psoriasis) and cancer.
"This guaranteed source of GMP grade reagents is vital to our product development especially for our pandemic and bioterrorism vaccine program," said Dr. Malcolm Skolnick, CytoGenix, Inc. President and CEO. "We are very pleased to enter into this agreement with GE Healthcare and look forward to working with them to expand the development of DNA-based pharmaceuticals," added Dr. Skolnick.
"We believe CytoGenix can effectively utilize GE's innovative disease research technologies with its own ground-breaking research to ultimately enhance the efficiency of healthcare delivery and increase the breadth of options for patient care," said Carl W. Fuller, Ph.D., Vice President Science Fellow at GE Healthcare.
April is not far away, just hope it's April 2006 :)
Bird Flu Death in Southern China
Sunday, March 05, 2006
HONG KONG — A respiratory disease expert says a 32-year-old man in a southern China province has been confirmed to have died of the deadly strain of bird flu.
Meantime, the World Health Organization is warning of the possibility of more human cases.
The man, who lived less than a two-hour train ride from Hong Kong, developed fever and pneumonia and died March 2.
The man's girlfriend is sick but shows no bird flu symptoms, while a dozen other people who had come into close contact with him have shown no symptoms.
A spokeswoman for the World Health Organization's China office says she has not received confirmation of the case from China's Health Ministry but warns that there could be more human cases anywhere in China.
Elsewhere, Poland has reported its first-ever cases in birds.
fearfrost, I hope you're right, 80% might be high
CYGX is still a very risky investment as you've heard on this board many times. Typically companies run out of working capital and fold if they cannot turn a profit after 11 years. IMO, this might be CYGX last few year(s) of trying.
themuzicmen, two possible outcomes IMO within the next 6 to 12 months
1. GE/Aldevron/Defense Department contract(s) or other collaboration(s) lead to CYGX revenue, even if it's only 6 figures, we're on the right track with a promising future for synDNA technology
2. No major changes in CYGX position, no revenue, no financing, CYGX continues to issue more PPOs diluting our value and continues to ask stockholders to support their continued "efforts" to make synDNA and related vaccines viable in the marketplace.
If #1 happens, we're flying
If #2 happens, I may consider selling part of my CYGX position and put my money elsewhere. Maybe maintain some CYGX as high risk potential, but the stock will no longer be a speculative buy, IMO
In other words, we can thank GE and Aldevron for whichever happens, synDNA either works or it doesn't. Hanging in there for another 6 to 12 months is fine with me.
Paulness - were you aware that Aldevron received a grant from the NIH for HIV vaccine testing about the same time they announced collaboration with CYGX on DNA vaccine testing (6 months ago). I noticed this on the Aldevron website in the PR section, wasn't sure if it was discussed here.
Do we know if CYGX and Aldevron are working on HIV now with CYGX? Same HIV testing that Malcomb mentioned in his late December web cast, which we are waiting on a PR.
Also, Aldevron received a Department of Defense contract 6 months ago to "develop a platform for the testing of vaccines instrumental in the nation’s fight against bioterrorism agents?"
Between GE and Aldevron, we should be getting some PR results soon, one would hope.
India Reports First Bird Flu Case
Saturday, February 18, 2006
BOMBAY, India — India reported its first case of the deadly H5N1 strain of bird flu on Saturday after chickens were found to have died from the virus. A man in Indonesia also died from the disease, that country's 19th death, officials said.
Indian officials will immediately begin slaughtering hundreds of thousands of birds in a 1.5-mile radius around the poultry farms in the western town of Navapur, where the confirmed cases were detected, Anees Ahmed, the Maharashtra state minister for animal husbandry, told The Associated Press.
"Around 500,000 birds will be killed," he said. "It is confirmed the deaths were caused by the H5N1 strain."
At least 30,000 chickens have died in Navapur, a major poultry-farming region of Maharashtra state, over the past two weeks, Ahmed said.
Officials initially believed the birds had died of Newcastle Disease, another deadly bird illness, but further tests revealed that bird flu was responsible.
Bird flu has killed at least 91 people — most in Asia — since 2003, according to World Health Organization figures updated through Monday.
Most victims have been directly infected by sick birds, but scientists fear the H5N1 virus could mutate to a form easily passed between humans and spark a human flu pandemic.
The Indonesian man died on Feb. 10 at a hospital in Jakarta. He had frequently been in contact with poultry, said Hariadi Wibisono, a Health Ministry official.
The death brings Indonesia's official toll from the virus to 19. The only country with more human deaths is Vietnam, with 42.
Minister of Health Affairs Siti Fadilah Supari said Saturday the government will boost its stockpile of anti-viral drug Tamiflu to four million pills in the next two months and 10 million by the end of the year.
Bird flu is becoming more virulent in Indonesia, Agriculture Minister Anton Apriyantono warned Wednesday.
He said that people were now "dying quicker" when they contracted the virus and that incidences of human cases were increasing.
"This likely means the virus is getting more ferocious," Apriyantono said.
He gave no data to back up his assertions, but World Health Organization figures for this year show eight human cases of bird flu in Indonesia, eight of which were fatal.
In 2005, there were 17 cases and 11 deaths, according to the group.
Egypt's agriculture minister said Saturday the number of cases of bird flu in the country were not high enough to warrant large-scale culling of poultry yet, but that authorities would act accordingly if the disease spreads.
The government on Friday announced the country's first cases of H5N1 — seven cases in three provinces.
"The disease is not at a level that leads to getting rid of large numbers" of fowl, Amin Abaza told the Arabic-language Al-Arabiya satellite channel. "There are known international measures that are taken. Poultry within a certain radius get culled."
He said those who work at the poultry farms were already trained and familiar with safety measures. Authorities were trying to spread awareness among families that raise poultry at home, he told Al-Arabiya.
"This came as no surprise. We have been preparing for this for a while," Abaza said of the disease.
In Germany, another 28 wild birds have been diagnosed with the deadly H5N1 bird flu on a north German island, an official said Saturday, bringing the total to 41.
Germany's first cases of bird flu were detected among dead swans and a hawk on the Baltic Sea island of Ruegen earlier this week.
ecmorgan - I agree, back to CYGX
...and the success we're hoping for in 2006 and beyond. Problem is, we're not getting details of what is to come, we can only guess.
PRs lately, although very positive, include only words like "we will intensify our product development efforts" and "increase our efforts to secure gov't contracts" and "proceed with development of synDNA™" and "maintain scientific research necessary to move the company forward".
Unfortuately words like intensify, increase, proceed and maintain do not pay the bills. This is NOT revenue specific news and there's no talk of financing this dream. I'm concerned they will issue more shares and dilute the pps. If we really have something, wouldn't a financing company be all over us for business? Maybe they are, we just don't know.
I'm a CYGX long (1999) with 100k shares and I've made a good amount of silver trading this stock over the years. I am very excited about this thing going to $5 pps, it's very possible within a year. However, right now we are limited to discussing Bioterrorism overhype and Bio tech industry news in general since CYGX is not telling us much.
Still excited though and hope for a revenue PR soon. That should make us fly. Good luck to all, enjoy the ride.
OT: neo43 what makes me feel better is knowing that you have worked all your professional life to help the disadvantaged, that is admirable. How's it working out?
OT: Sanoman great article, I'm with you and scootergirl 100% on this. Liberals are happy to waste money on programs that are dumbing down america, handing freeloaders our hard earned money and no reason to get off the couch and work for it, yet they have an issue with throwing money at real issues that could easily lead to disaster. They are clueless.
To say that bioterrorism is overhyped is one naive statement. That would be impossible IMO because protecting our national security is the #1 priority of our gov't. How could people believe Milton's naive thinking? Lots do because they think the same way. And like you said, they would be the first ones to blame the gov't if there was an attack.
And secondly, to say that overhyping bioterrorism is making the situation worse is another liberal fantasy that is messed up IMO. Does he really think that the bad guys wouldn't find another way to distroy us if we didn't talk about the real threat of bioterrorism?
Reminds me of Archie Bunker's immortal words when Gloria stated the murder rate with guns had increased from one year to the next... "would you be happier little girl if they was all pushed out of windows?"